CJC-1295 vs Pegzilarginase-nbln

A side-by-side comparison from PeptideSciences101, the open peptide reference.

Overview

CJC-1295 is primarily a performance & growth peptide, while Pegzilarginase-nbln is used for weight management & metabolic.

This page compares CJC-1295 and Pegzilarginase-nbln across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

CJC-1295Pegzilarginase-nbln
CategoryPerformance & GrowthWeight Management & Metabolic
Regulatory status (US)Research use onlyFDA approved
Typical dosage1-2 mg
Frequencyweekly
Reported benefitsIncreased muscle mass, fat loss, improved recovery, better sleep, enhanced bone density
Reported side effectsWater retention, joint pain, potential insulin resistance with prolonged use

Key differences

Primary use. CJC-1295 is categorised under Performance & Growth, while Pegzilarginase-nbln falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.

Regulatory status. CJC-1295: not FDA-approved; treated as a research compound. Pegzilarginase-nbln: FDA-approved.

Dosing. CJC-1295 is typically dosed at 1-2 mg (weekly). Typical dosing for Pegzilarginase-nbln is not catalogued.

Can you stack them?

Some protocols combine peptides, but stacking CJC-1295 and Pegzilarginase-nbln has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between CJC-1295 and Pegzilarginase-nbln?
CJC-1295 is primarily a performance & growth peptide, while Pegzilarginase-nbln is used for weight management & metabolic. CJC-1295 is not FDA-approved; generally classified as a research compound, whereas Pegzilarginase-nbln is FDA-approved for one or more indications.
What is CJC-1295 used for?
Growth hormone, muscle mass, fat loss.
What is Pegzilarginase-nbln used for?
PEGylated recombinant arginase enzyme for Arginase 1 Deficiency. FDA approved February 23, 2026.
Can you take CJC-1295 and Pegzilarginase-nbln together?
Some users combine peptides within a single protocol, but stacking CJC-1295 and Pegzilarginase-nbln has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
Is CJC-1295 or Pegzilarginase-nbln FDA-approved?
CJC-1295 is not FDA-approved; generally classified as a research compound. Pegzilarginase-nbln is FDA-approved for one or more indications.

Read the full articles

  • CJC-1295 — full monograph: mechanism, research, dosing & references
  • Pegzilarginase-nbln — full monograph: mechanism, research, dosing & references

More Performance & Growth comparisons

CJC-1295 compared across categories

← All peptide comparisons